Podcasts about kidney week

Gabs e Fer batem um papo sobre o evento que aconteceu em San Diego no fim de outubro desse ano, e quando os grandes especialistas em nefrologia se reúnem para apresentar grandes novidades, além de ser um espaço para troca de experiências, para network e também para turismo!

We had a great NephJC get together. We recorded the whole event and packaged it into a podcast.Musical entertainmentTim Yau (@Maximal_Change)Too Sweet by HozierFairy Tale of New York by written Jem Finer and Shane MacGowan. Hear it performed by the Pogues.Interview of Tom MuellerTom Mueller author of How to Make a KillingJade Teakall@jmteakellGraham Abra@GrahamAbraInterview of Tom MuellerTom Mueller author of How to Make a KillingJade Teakall @jmteakellGraham Abra @GrahamAbraNephMadness logo revealNephJC KidneysNephJC blog postNephJC Manuscript of the Year: Flow accepted by Meg JardineManjula Kurella Tamura, winner of the 2015 NephMadness, oh and author of NEJM manuscripts and subject of a NYT article.NephJC Visual Abstract of the Year: Corina Teodusiu, creator of the Flozinator logoNephJC Social Justice Award: ISN petition to the WHO on Kidney HealthMost Engaged Scientist Award: Michelle RheaultRookie of the Year: Milagros FloresMVP: Christina PopaNephJC Founders Award: Joshua WaitzmanNathan Hellman Social Media Project of the Year: Edgar Lerma and the ASN Visual Abstract TeamMore Music with TimSaginaw, Michigan as performed by Johny CashBetty, written by Taylor SwiftThe Kidney ConnectionFreely Filtered Kidney Week DraftPrevious drafts2021 ASN Kidney Week Draft2022 ASN Kidney Week Draft2023 ASN Kidney Week DraftList of all the simultaneous publications from Kidney Week 2024Sophia: SMART Trial (Link goes to the new KidneyCompass podcast that interview lead author Hiddo HeerspinkJordy's editorial in the European Heart Journal. LinkJosh: APPLAUSE Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy in the NEJMAPPLAUSE results announcement at The World Congress of Neophrology in Buenos AriesIptapocan is a factor B inhibitionJordy: POISE-3 with simultaneous publication in KIMentions she wanted to pick KAT-AKI because she worked with Perry Wilson.Per Nayan, Amit Garg is the Beyonce of NephrologyAccord Trial (NEJM)Joel: HSK21541 for PruritusCorrection link to source (graph)Nayan: FINEARTS-HF with simultaneous publication in JACCBARACH-D: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial (Nature Medicine)Swapnil comes out as a SpiroStanTOPCAT funny businessPATHWAY-2 Trial (NephJC coverage)Swap: K Bath and cardiac arrhythmia with simultaneous publication in Kidney InternationalCAST: A study that rocked the cardiology world and became the poster child for evidence-based medicine (Link)Tubular SecretionsSwap: Late breaking and high impact sessionsNayan: Intro to…Joel: Student poster on blood pressure techniqueJordy: The Penguin. A couple of mentee postersSophie: Tracks her sessions on paper.Josh: Quiz and Questionaire session with JC Velez, Bea Concepcione, Anna Burgner, Roger Rodby.

Hosts Tod Ibrahim and David White discuss give a rundown of the policy related events of Kidney Week 2024 in San Diego, CA.

Hosts Tod Ibrahim and David White discuss give a rundown of the policy related events of Kidney Week 2024 in San Diego, CA.

Swapnil Hiremath, MD, MPH, FASN, joins Hiddo Heerspink, PhD, and Meg Jardine, MBBS, PhD, to discuss clinical trials presented at Kidney Week 2024, including notable findings from accepted submissions and late-breaking clinical trial sessions.

Swapnil Hiremath, MD, MPH, FASN, joins Hiddo Heerspink, PhD, and Meg Jardine, MBBS, PhD, to discuss clinical trials presented at Kidney Week 2024, including notable findings from accepted submissions and late-breaking clinical trial sessions.

Kidney Week 2024 on the go. Gentzon Hall, MD, PhD, FASN, Matthias Kretzler, MD, and Heather Reich, MD, PhD, discuss progress in glomerular disease research, emerging trends, and clinical challenges.

Leading health care professionals Edwina A. Brown, MD, MBChB, Timothy Ray, CNN, CNN-NP, DNP, NP, and Monnie Wasse, MD, MPH, FASN, share their perspectives on evolving advances in dialysis treatments and patient care in the US and across the globe.

Kidney Week 2024 on the go. Gentzon Hall, MD, PhD, FASN, Matthias Kretzler, MD, and Heather Reich, MD, PhD, discuss progress in glomerular disease research, emerging trends, and clinical challenges.

Leading health care professionals Edwina A. Brown, MD, MBChB, Timothy Ray, CNN, CNN-NP, DNP, NP, and Monnie Wasse, MD, MPH, FASN, share their perspectives on evolving advances in dialysis treatments and patient care in the US and across the globe.

JASN encourages investigators to submit their late-breaking clinical trial manuscripts for rapid consideration and peer review and, if accepted, online publication in JASN concurrent with Kidney Week.

Ronny Coombs, a graduate of George Mason University, is exhibits manager for the American Society of Nephrology (ASN). Her main focus is Kidney Week, a medical conference that attracts 14,000 attendees and, on average, 170 to 200 exhibitors annually. Pandemic Pivot During the Covid shutdown, the ASN didn't cancel its events, just the in-person component. “Doctors still need their education and research was still happening. We had our first virtual event in November of 2020, which was difficult in another way. We were trying to learn how to suddenly become a technology expert and a user experience designer and all these other things that I had never had to do before. We really lucked out. I mean, our event went off really well,” said Coombs. “It was just a whole other different kind of difficult, it was a rough couple of years for everybody in our industry.” Impact of Visa Issues Historically, 40% of Kidney Week attendees are international. At present, that number is in the high 30%. Coombs says this is a result of visa issues. “The wait times right now are prohibitive. People can't get here,” she says. No Replacement for In-Person Events Doctors could attend virtual events during the pandemic and get their certifications. “But we found attendance at the virtual sessions was really low, whereas in person, we have rooms overflowing,” she says. AI is the Future “If you look at where we were as a society 60 years ago versus today and what that will look like over the next 20 or 30 years, the growth that'll happen, I think it's fun to watch, and I am excited to be a part of it,” she says. “I've enjoyed specifically the impact that AI has had on our industry, and me as well.” She uses it to help her with creative blocks. “AI is not going to replace us, but it is a really good space for inspiration, and that's how I typically use it,” she said. Sustainability Coombs witnessed the focus on sustainability slowing during the pandemic, but she is heartened by the recent shift back. “It's super important to me, in both my personal and professional life, that I'm being cognizant of the health of our planet,” she said. The Taylor Swift Effect Coombs has been a Swiftie since she was 15 years old. “I admire her tenacity so much. Her refusal to accept being shut down or being told this is the way that things are going to be. She's such a strong, willful individual, and she just doesn't allow herself to be muted. I've taken that a lot into my life in moments where I may have stayed quiet or allowed someone else to make a decision for me,” she explained. Swift's ability to make her fans special is something Coombs emulates in the events she plans and in her relationships. Importance of Mentors While a student at George Mason, Vicki Johnson of Vicki Johnson & Associates, which has since been acquired by Cypress Planning Group, was a guest speaker. At the end of her talk, Johnson shared her business card to continue the conversation. Coombs took advantage of the offer, and Johnson became her mentor, helping her land her first job in the industry.

CME credits: 1.00 Valid until: 12-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/experts-on-the-ground-new-data-and-practical-clinical-integration-of-therapies-approved-for-igan/24046/ Expert Nephrologist Pietro Canetta, MD, MS, gives an overview of top abstracts from Kidney Week 2023 and new therapies for IgAN.=

CME credits: 0.25 Valid until: 12-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/experts-on-the-ground-data-updates-on-emerging-therapies-for-igan/24045/ Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.=

Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.

Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.

New Introduction • Christina having seizures!! So scary and she is one strong chick! • Appendix BURST!! Tube in stomach, Mike the dinosaur • NKF Washington DC summit 2023 • NANT conference 2023 meeting Sam and Lacye Trevino • Lobby days, meeting people in Idaho and Utah! • Boston 2023 Meeting our hero's and idols! • Moving Mersadies to Utah, we are becoming grandparents! • California conference 2023 first RV lobby day, doing dialysis in RV. • ASN 2023 KIDNEY WEEK, Surprised Christina with WICKED • Meeting Candice Madden in Washington DC. Scott Ricks lost his wife Katie Rick's during dialysis treatment #BLINDCHICKLIVING #LIVINGondialysis --- Send in a voice message: https://podcasters.spotify.com/pod/show/blindchickliving/message

Este pódcast está destinado exclusivamente a profesionales de la salud. En esta semana se revisan los principales estudios del congreso más relevante para los nefrólogos, Kidney Week 2023: DUPLEX, PROTECT y ZENITH-CKD. Nuestro invitado: Dr. Manuel Alejandro Márquez Martínez (X: kidney_power) Notas: https://espanol.medscape.com/verarticulo/5910527 Time stamps Introducción… 00:00 Presentación Dr Marquez… 00:30 Recomendaciones de la semana… 02:00 Kidney week… 05:50 Preámbulo… 07:40 DUPLEX… 08:20 PROTECT… 14:00 ZENITH-CKD… 20:25 Inhibición de la síntesis de aldosterona… 26:50 Puntos para llevar a casa… 32:00  

After attending ASN Kidney Week, Bluestar Principal Jeff Fineberg sits down with Dr. Pietro Canetta to talk all things IgA nephropathy (IgAN). After Dr. Canetta provides a brief summary of his IgAN lecture at Kidney Week, Emerging Therapeutic Options in IgA Nephropathy, the two discuss the Filspari (sparsentan) data presented from both the PROTECT study, in IgAN, the DUPLEX study, in FSGS. From there, Dr. Canetta opines on the value of surrogate endpoints in predicting the three D's of CKD: death, dialysis, and doubling of serum creatinine (SCr). Dr. Canetta briefly discusses Novartis' press release announcing the positive Phase II data with atrasentan, another ETA RA, before the conversation shifts to other drug classes and therapeutic targets, including SGLT2 inhibitors, and B-cell activation (i.e., APRIL/BAFF). Finally, Jeff asks Dr. Canetta about whether the recent advancements in IgAN are generalizable to other glomerular diseases, and what might be the determinants of this. Jump to specific topics in the conversation: 00:00 Recap + guest intro/bio + Kidney Week lecture summary 05:05 Filspari (sparsentan) trial results from PROTECT (IgAN) and DUPLEX (FSGS) 12:25 Value of surrogate endpoints in predicting three D's - death, dialysis, and doubling of SCr - in glomerular disease 19:55 Atrasentan press release 23:05 The "four-hit" hypothesis of IgAN pathogenesis and SGLT2i 26:10 B-cell activation (APRIL/BAFF) as a therapeutic approach in IgAN 31:55 Generalizability (and lack thereof) of therapeutic approaches to other glomerular diseases 37:25 Where to learn more Helpful links: PROTECT Study (Filspari/sparsentan in IgAN) DUPLEX Study (Filspari/sparsentan in FSGS) Novartis press release (atrasentan in IgAN) ENVISION Study (sibeprenlimab in IgAN) Columbia Glomerular Center For more information about Bluestar BioAdvisors, please visit our website.

Novembro é o mês clássico da Kidney Week, o famoso e inigualável congresso da Sociedade Americana de Nefrologia, que esse ano ocorreu na Filadélfia, Pensilvânia. Foram mais de 12.000 participantes dos mais diversos países, com uma programação sem igual. E é claro que nós do Nefropapers não poderíamos ficar de fora! Nesse episódio trazemos nossas impressões e as principais novidades trazidas durante o congresso!! Participaram do episódio Gabes, Igor e Raquel. 00:01 - 2:50 Introdução e Agenda 2:51 - 7:30 Participação Brasileira 7:31 - 11:05 Oportunidades de Network 11:05 - 18:00 Destaques do Congresso - Genética 18:01 - 28:20 Doenças glomerulares e terapia multitarget na DRC 28:21 - 32:41 Diálise Domiciliar 31:42 - 40:00 Formatos fora da caixa 40:01 - 42:30 Mensagens finais

The Filtrate:Joel TopfSwapnil HiremathSophia AmbrusoAC GomezJosh WaitzmanJennie LinNayan AroraThe CurbsidersMatt F. Watto (@DoctorWatto)Paul Nelson Williams, America's primary care physician (@PaulNWilliamz)With Special Guest:JD Foster (@KidneyVet)Sayed Tabatabai (@TheRealDoctorT) Nephrologist in Austin and the author of These Vital SignsMichelle Rheault (@rheault_m) Chief of Pediatric Nephrology at the University of Minnesota and lead author of the DUPLEX TrialEditor:Joel TopfShow Notes:Lily toxicity in the cat (PubMed)Surgeons perform kidney transplants in cats amid rising demand for advanced pet care (ABC News)Treatment of ibuprofen toxicity with serial charcoal hemoperfusion and hemodialysis in a dog (PubMed)Nephrology in Veterinary Medicine (Kidney 360)Star Wars Society of San Antonio (FaceBook)These Vital Signs (Amazon)Dr Tabatabai read a short story called The Handholder, here is the original tweet thread for that story (ThreadReader)The pearl not the patient (PubMed)Late Braking and High Impact Clinical Trial press releaseMENTOR, Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy, was in 2019 not 2017 (NEJM)KALM-1, A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus, was in 2019 not 2017 (NEJM)Sophie's number one pick: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Lancet)Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058).Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration (AJKD)AC Gomez's Pick: MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients (ASN-Online.org) Josh's Pick: A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (NEJM)Nayan's Pick: The EnAKT LKD Cluster Randomized Clinical Trial (JAMA Internal Medicine) The Freely Filtered simultaneous release (NephJC)Freely Filtered is now a verb. Swap's Pick: Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D) (ASN-Online.org)Joel's Pick: AYAME Study: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Bardoxolone Methyl in Diabetic Kidney Disease (DKD) Patients (ASN-Online.org)Reata is a no-show to the 2012 ASN Kidney Week (PBFluids)Michelle's Pick: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The DUPLEX Study (NEJM)DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)

In this episode, discover what Nisha Bansal, MD, FASN, and Ankur Shah, MD, FASN, consider this year's highlights. They will dive into Kidney Week highlights, community interactions, and kidney health.

In this episode, discover what Nisha Bansal, MD, FASN, and Ankur Shah, MD, FASN, consider this year's highlights. They will dive into Kidney Week highlights, community interactions, and kidney health.

In this episode, Raad Bin Zakir Chowdhury, MD, FASN, and Deepak Chandramohan, MD, discuss their experiences with the evolving directions and tools for kidney care treatment with Angie S. Lobo, MD, moderating the conversation.

In this episode, Raad Bin Zakir Chowdhury, MD, FASN, and Deepak Chandramohan, MD, discuss their experiences with the evolving directions and tools for kidney care treatment with Angie S. Lobo, MD, moderating the conversation.

In this episode, George L. Bakris, MD, MA, FASN, and Duc H. Quach, MD, discuss day 2 of Kidney Week.

In this episode, George L. Bakris, MD, MA, FASN, and Duc H. Quach, MD, discuss day 2 of Kidney Week.

In this episode, Joel M. Topf, MD, hosts the discussion with Jennie Lin, MD, MS, FASN and patient advocate, Precious McCowan, MS, as they dive into experiences with kidney disease and the key takeaways from the Early Program sessions.

In this episode, Joel M. Topf, MD, hosts the discussion with Jennie Lin, MD, MS, FASN and patient advocate, Precious McCowan, MS, as they dive into experiences with kidney disease and the key takeaways from the Early Program sessions.

In the first ever Biotech Matters podcast episode, Principal Jeff Fineberg, PhD, sits down with nephrologist Beatrice Goilav, MD, to talk all things Kidney Week. Dr. Goilav offers her thoughts on an ideal day-by-day itinerary, as well as her hopes for what will be presented at a variety of sessions, including drug trials in IgAN, and new studies of SGLT2 inhibitors. She also offers her perspective on the potential for complement inhibitors in glomerular diseases, and which of these drugs in development she is most interested in. Finally, she makes some recommendations on poster abstracts to visit in the exhibit hall. For more information about Bluestar BioAdvisors, please visit our website. Dr. Goilav hangs out on X (formerly known as Twitter) @BGoilav. Her DM is open to episode listeners with follow-on questions.

In Episode 11, guests Jordy Cohen & Samir Parikh (and members of the American Society of Nephrology Kidney Week Education Committee) join us for a discussion about Kidney Week 2023 and their careers as physician-scientists. They discuss their journeys to their current careers, what inspired them to pursue nephrology ("beautiful ribbons of anti-GBM"), and share their advice for trainees. For more on Kidney Week 2023, here's a Doximity op-ed.Nephrons: Matthew Sparks, Samira FaroukGuests: Jordy Cohen, Samir ParikhLinks from the Show:02:03: PLA2R & Membranous Nephropathy (2009)04:03: Sflt-105:05: FLOW & GLP-105:55: ACC HTN Guidelines (2017)09:33: Bill McKibben Plenary: Too Hot & Inhuman Temperatures10:45: Climate change & heat stress nephropathy11:00: Ardem Patapoutian Plenary: How Do You Feel? The Molecules that Sense Touch 13:03: Obesity & RAS Activation (Mice)

Este pódcast está destinado exclusivamente a profesionales de la salud. Kidney week o la semana del riñón, es el congreso anual que organiza la American Society of Nephrology (ASN), y es la reunión de mayor relevancia para la comunidad médica de nefrólogos. En esta en el pódcast se presentan los principales estudios.  Nuestro invitado: Dr. Manuel Alejandro Márquez Martínez (Tw: @Kidney_Power) Notas: https://espanol.medscape.com/verarticulo/5910315 Time stamps Introducción… 00:00 Presentación Dr. Marquez… 00:40 Recomendaciones de la semana… 02:15 Kidney Week… 8:38 EMPA-Kidney… 11:10 STOP-ACEi… 19:45 Best Fluids… 28:35 Puntos para llevar a casa… 37:15

The Filtrate:Joel TopfSwapnil HiremathNayan AroraSophia AmbrusoEditor: Nayan AroraShow Notes:Joel's Conflict of Interest StatementThe Draft Board EMPA-Kidney is “off the board”Lunch Symposium on Current and Future Approaches to the Diagnostic Assessment and Management of AKI in Patients with Cirrhosis provided by an educational grant from Mallinckrodt PharmaceuticalsThe CONFIRM Trial Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome in NephJCClinical Practice Session Leveraging Social Media to Create, Learn, Teach, Advocate, and Dispel MisinformationThe BEST-Fluids Trial: A Randomized Controlled Trial of Balanced Crystalloid Solution vs. Saline to Prevent Delayed Graft Function in Deceased Donor Kidney Transplantation - Michael G. Collins, Magid Fahim, Elaine Pascoe, Carmel Hawley, David W. Johnson, Philip A. Clayton, Steven J. Chadban (ClinicalTrials.gov)The Late Breaking and High Impact Trials Session line upStop ACEiCLARITY Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trialEffects of Pantoprazole on Kidney Outcomes: Post Hoc Analyses From the COMPASS Randomized Controlled Trial by Lonnie Pyne, et alNo Stone: Hydrochlorothiazide for the Prevention of Kidney Stone Recurrence by Daniel Foster, et alMyTEMP: Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trialClinical Practice Session Best of NephJC“We'd Now Like To Open The Floor To Shorter speeches disguised as questions.”ASN Task Force on the Future of NephrologyAttracting Osteopathic Medical Students Into NephrologyHasan Minhaj's joke at the expense of DOsTRANSFORM-HF: Torsemide vs. Furosemide in Treating Patients With HFPoint-of-Care Ultrasound in Nephrology specifically VExUS

In this episode, Catherine Godson, PhD, leads a discussion with Orlando M. Gutierrez, MD, and Josh Waitzman, MD, PhD, on day 3 of Kidney Week.

In this episode, Catherine Godson, PhD, leads a discussion with Orlando M. Gutierrez, MD, and Josh Waitzman, MD, PhD, on day 3 of Kidney Week.

In this episode, ASN Kidney Week Committee Co-Chair Kirk Campbell, MD, FASN, leads a discussion with Precious McCowan, MS, and Amy Mottl, MD, MPH, FASN, about day 2 of Kidney Week.

In this episode, ASN Kidney Week Committee Co-Chair Kirk Campbell, MD, FASN, leads a discussion with Precious McCowan, MS, and Amy Mottl, MD, MPH, FASN, about day 2 of Kidney Week.

In this episode, ASN President Susan E. Quaggin, MD, FASN, leads a discussion with S. Ananth Karumanchi, MD, and Rachel Lennon, MBBS, PhD, about day 1 of Kidney Week and returning to an in-person program.

In this episode, ASN President Susan E. Quaggin, MD, FASN, leads a discussion with S. Ananth Karumanchi, MD, and Rachel Lennon, MBBS, PhD, about day 1 of Kidney Week and returning to an in-person program.

In Episode 6, guests Catherine Godson, PhD & Kirk Campbell join us for a discussion about their careers as physician-scientists. They discuss their journeys to their current careers, the "moment" they knew research was the career for them, and share advice for trainees. American Society of Nephrology 2022 Kidney Week Program Co-Chairs Dr. Godson & Dr. Campbell also give us a sneak peak into this year's conference, which starts November 3rd. Nephrons: Sam Kant, Matthew Sparks, Samira FaroukGuests: Catherine Godson, Kirk Campbell

Guest: John Friedewald, MD The 2021 American Society of Nephrology Annual Meeting covered everything from inequities in organ allocation to policy updates. Here to share those and other key takeaways from the conference is Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine.

 Did you know? According to a report published by the WHO, adherence rates in developed countries average only about 50%, and there is little data about adherence in countries where access to care is more limited or consistent. Adherence is a key factor associated with the effectiveness of all pharmacological therapies but is particularly critical for medications prescribed for chronic conditions. Of all medication-related hospitalizations that occur in the United States, between one-third and two-thirds are the result of poor medication adherence. Inadequate adherence also is a major player in adverse events to medications. Welcome to this episode of Physician's Weekly Podcast. My name is Dr Rachel Giles, from Medicom Medical Publishers, in collaboration with Physician's Weekly. We have 3 fantastic in-depth interviews for you this week, touching on improved hospital workflow for stroke patients, a presentation on management of gout in dialysis patients, and medication experience. In this 31st episode of the Physician's Weekly Podcast, we speak with Dr Danny Sands, about addressing barriers such as understanding their condition, cultural issues, and denial can help patients avoid adverse effects from poor medication adherence. Dr Sands is a primary care physician at Beth Israel Deaconess Medical Center, and is a founder and co-chair of the board of the Society for Participatory Medicine. In 2009 he was recognized by HealthLeaders Magazine as one of “20 People Who Make Healthcare Better.”Also in this episode, we speak with Dr Anthony Bleyer, Professor of nephrology at the Wake Forest School of Medicine, North Carolina, about his presentation of the results of a cohort study into the prevalence, risk factors and outcomes of gout in dialysis patients at the Kidney Week of the American Society of Nephrology, which was held virtually 4-7 November, 2021 [1].But first, Physician's Weekly speaks with Ferdinand Hui, about workflow optimization and mobile technology. Dr. Hui hails from Johns Hopkins – but is currently working in Hawaii- and we talk about the deluge of communication apps in hospitals and what makes something valuable, versus noise. He recently published a paper in Journal of Neurointerventional Surgery [2] on the impact of mobile apps on treatment times for patients with stroke where time is of the essence. His team showed that that utilization of RapidAI mobile application can significantly reduce treatment times in stroke care by accelerating the process of mobilizing stroke clinicians and interventionalists.Enjoy listening!Further reading:1.      Bleyer AJ, et al. Risk Factors and Outcomes of Gout in Dialysis Patients: A Cohort Study of the United States Renal Data System (USRDS). PO0792, American Society of Nephrology: Kidney Week 2021, 04-07 November.2.      Murray NM, Unberath M, Hager GD, Hui FK. Artificial intelligence to diagnose ischemic stroke and identify large vessel occlusions: a systematic review. J Neurointerv Surg. 2020 Feb;12(2):156-1Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Guest: John Friedewald, MD What did the first day of the American Society of Nephrology's Kidney Week 2021 showcase? From COVID-19 to developments in kidney disease, Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine, shares highlights from Day 1.

Guest: John Friedewald, MD Kidney Week 2021 tackled everything from kidney transplants to systemic inequities. Here to share his insight on the latest updates is Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine.

Dr. Michelle Josephson, Dr. Mukta Baweja, and Dr. Laura Maursetter discuss ASN's "United 4 Kidney Health" campaign, particularly the priorities to intervene earlier and reduce disparities in kidney care.

Dr. Michelle Josephson, Dr. Mukta Baweja, and Dr. Laura Maursetter discuss ASN's "United 4 Kidney Health" campaign, particularly the priorities to intervene earlier and reduce disparities in kidney care.

Tod Ibrahim, Dr. Kirk Campbell, and Dr. Catherine Godson talk about the legacy of the late Dr. Barbara Murphy, including her professional work and personal nature.

Tod Ibrahim, Dr. Kirk Campbell, and Dr. Catherine Godson talk about the legacy of the late Dr. Barbara Murphy, including her professional work and personal nature.

ASN President Dr. Susan Quaggin talks to Dr. Katherine Tuttle about the latest developments in the field of diabetic kidney disease.

ASN President Dr. Susan Quaggin talks to Dr. Katherine Tuttle about the latest developments in the field of diabetic kidney disease.